Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Chimerix
Biotech
Chimerix had 8 suitors: Why Jazz won out
Chimerix considered the downward market trend for biopharma and a general volatility tied to escalating global tensions when assessing Jazz's offer.
Gabrielle Masson
Mar 21, 2025 5:17pm
Jazz hands Chimerix $935M to buy near-approval cancer drug
Mar 5, 2025 8:13am
Chimerix CEO replaced by a trio of officers—Chutes & Ladders
Feb 8, 2019 9:00am
Chimerix’s CEO departs and is replaced by a trio of officers
Feb 6, 2019 2:10pm
Merck’s letermovir hits Phase III target
Oct 19, 2016 7:48am
Chimerix now 0 for 2 as brincidofovir flunks another PhIII trial
May 9, 2016 9:08am
